Cancer

Protherics PLC provides Voraxaze Update

Published in Medical Letter on the CDC and FDA, June 10th, 2007

Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today provided an update on its Voraxaze(tm) marketing applications in the US and EU. Voraxaze(tm) is an adjunctive therapy for patients with impaired renal function who are experiencing, or at risk of, toxicity from methotrexate ("MTX"), a widely used anti-cancer agent.

Following recent successful discussions with the Food and Drug Administration ("FDA"), Protherics has agreed to provide additional manufacturing and stability data requirements to support a Biologicals License Application ("BLA") for Voraxaze(tm) in the US. The FDA has also...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry